PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.88%
Revenue growth of 4.88% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
5.75%
Gross profit growth of 5.75% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
12.67%
EBIT growth exceeding 1.5x Medical - Pharmaceuticals median of 5.36%. Joel Greenblatt would examine whether a unique competitive edge supports this outperformance.
12.67%
Operating income growth exceeding 1.5x Medical - Pharmaceuticals median of 4.08%. Joel Greenblatt would see if unique processes drive exceptional profitability.
-3.27%
Negative net income growth while Medical - Pharmaceuticals median is 2.20%. Seth Klarman would investigate factors dragging net income down.
-3.27%
Negative EPS growth while Medical - Pharmaceuticals median is 2.40%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-3.27%
Negative diluted EPS growth while Medical - Pharmaceuticals median is 3.07%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.14%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.11%. Seth Klarman would see an advantage if others are still diluting.
-100.00%
Dividend cuts while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
25.34%
10Y revenue/share CAGR 50-75% of Medical - Pharmaceuticals median of 39.80%. Guy Spier would worry about subpar top-line expansion over the long run.
48.58%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 11.64%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
25.30%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 16.16%. Joel Greenblatt might see a short-term competitive advantage at play.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.18%
Below 50% of Medical - Pharmaceuticals median. Jim Chanos would suspect deeper issues limiting long-term profit growth.
39.74%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 4.91%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
28.36%
3Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 16.15%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
151.08%
Equity/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 67.96% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
101.86%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 31.93%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
50.02%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 14.98%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.35%
AR growth of 35.35% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
-2.20%
Decreasing inventory while Medical - Pharmaceuticals is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
2.82%
We expand assets while Medical - Pharmaceuticals is negative. Peter Lynch sees a possible advantage if expansions align with profitable markets or a recovering cycle.
2.57%
Positive BV/share change while Medical - Pharmaceuticals median is negative. Peter Lynch finds a strong advantage vs. peers failing to expand equity.
-57.60%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
83.47%
SG&A growth far above Medical - Pharmaceuticals median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.